Effect of dehydroepiandrosterone administration on fatigue, well-being, and functioning in women with primary Sjogren syndrome

Autor: A. Hartkamp, Rinie Geenen, G. L. R. Godaert, Hendrika Bootsma, Aike A. Kruize, R. H. W. M. Derksen, Jwj Bijlsma
Přispěvatelé: Translational Immunology Groningen (TRIGR)
Jazyk: angličtina
Rok vydání: 2008
Předmět:
Placebo-controlled study
PLACEBO-CONTROLLED TRIAL
law.invention
DOUBLE-BLIND
Quality of life
Randomized controlled trial
Oral administration
law
Immunology and Allergy
Medicine
Testosterone
CLASSIFICATION CRITERIA
Treatment Failure
SYSTEMIC-LUPUS-ERYTHEMATOSUS
DHEA
ANDROGEN-DEFICIENT
Fatigue
Pain Measurement
PSYCHOMETRIC QUALITIES
Dehydroepiandrosterone Sulfate
Middle Aged
Sjogren's Syndrome
Female
hormones
hormone substitutes
and hormone antagonists
Adult
ELDERLY-WOMEN
medicine.medical_specialty
Immunology
Dehydroepiandrosterone
Blood Sedimentation
Placebo
General Biochemistry
Genetics and Molecular Biology
CLINICAL-TRIAL
REPLACEMENT THERAPY
Double-Blind Method
Rheumatology
Internal medicine
Humans
Aged
Psychiatric Status Rating Scales
Chi-Square Distribution
business.industry
Clinical trial
Affect
stomatognathic diseases
Quality of Life
Physical therapy
business
Chi-squared distribution
Zdroj: Annals of the Rheumatic Diseases, 67(1), 91-97. BMJ PUBLISHING GROUP
ISSN: 1468-2060
0003-4967
Popis: Dehydroepiandrosterone (DHEA) administration has been reported to improve fatigue, psychological distress, and physical disability. These are common features of primary Sjögren syndrome (pSS). We investigated the effects of DHEA administration on fatigue, well-being, and functioning in women with pSS.In a double-blind, randomised placebo-controlled clinical trial, 60 female patients with pSS received 200 mg oral DHEA or placebo. Primary outcome measures were general fatigue, depressive mood, mental well-being, and physical functioning. In addition, pain, sicca complaints and disease activity parameters were measured. Patients were assessed before treatment, after 3, 6, and 12 months on study medication, and 6 months after cessation of treatment.Patients from both the DHEA- and placebo-treated group improved on general fatigue (p0.001), mental well-being (p = 0.04), and depressive mood (p = 0.008). Physical functioning did not change (p = 0.44). Of the secondary outcome variables, complaints of a dry mouth diminished during treatment in both groups (p = 0.006), the erythrocyte sedimentation rate showed a decrease for the DHEA group (p = 0.02), and complaints of dry eyes improved in the placebo group (p = 0.01). The belief to have used DHEA was a stronger predictor for improvement of fatigue and well-being than the actual use of DHEA.Our study does not support a superior effect of DHEA over placebo in female patients with pSS. Both DHEA and placebo induce improvement of fatigue and well-being. This may suggest possibilities for cognitive behavioural interventions.
Databáze: OpenAIRE
Externí odkaz: